for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck KGaA

MRCG.DE

Latest Trade

148.90EUR

Change

-0.80(-0.53%)

Volume

355,189

Today's Range

147.95

 - 

149.80

52 Week Range

76.22

 - 

149.95

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
149.70
Open
149.05
Volume
355,189
3M AVG Volume
9.73
Today's High
149.80
Today's Low
147.95
52 Week High
149.95
52 Week Low
76.22
Shares Out (MIL)
434.78
Market Cap (MIL)
19,244.17
Forward P/E
22.37
Dividend (Yield %)
0.87

Next Event

Full Year 2020 Merck KGaA Earnings Release

Latest Developments

More

Merck Buys Hamburg-Based AmpTec

Merck Expands Life Science Production Capacities In The United States

Artios And Merck KGaA Announce Global Strategic Collaboration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck KGaA

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Performance Materials business provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.

Industry

Major Drugs

Contact Info

Frankfurter Str. 250

64293

Germany

+49.6151.720

https://www.merckgroup.com/

Executive Leadership

Wolfgang Buechele

Independent Chairman of the Supervisory Board

Stefan Oschmann

Chairman of the Executive Board and Chief Executive Officer

Michael Fletterich

Independent Vice Chairman of the Supervisory Board, Employee Representative

Marcus Kuhnert

Member of the Executive Board, Chief Financial Officer

Udit Batra

Chief Executive Officer Life Science, Member of the Executive Board

Key Stats

2.21 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

15.3K

2018

14.8K

2019

16.2K

2020(E)

17.4K
EPS (EUR)

2017

6.160

2018

5.100

2019

5.560

2020(E)

6.656
Price To Earnings (TTM)
34.38
Price To Sales (TTM)
1.11
Price To Book (MRQ)
3.69
Price To Cash Flow (TTM)
5.18
Total Debt To Equity (MRQ)
76.19
LT Debt To Equity (MRQ)
55.65
Return on Investment (TTM)
5.74
Return on Equity (TTM)
4.43

Latest News

Latest News

Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs

Germany's Merck KGaA said on Thursday it has agreed a three-year strategic research deal worth up to $6.8 billion with Artios Pharma Limited to develop up to eight potential drugs for cancer by targeting DNA repair mechanisms inside cells.

Merck KGaA inks research deal with Artios for cancer drugs

Germany's Merck KGaA said on Thursday it has signed a three-year strategic research deal with Artios Pharma Limited to discover and develop up to eight potential targeted treatments for cancer.

Merck KGaA lifts earnings guidance on demand for lab tools

Healthcare and chemicals group Merck KGaA <MRCG.DE> lifted its guidance for full year earnings after the scramble to ready treatments and vaccines against the coronavirus bolstered demand for its supplies for biotech labs.

Merck KGaA lifts full-year earnings guidance

Healthcare and chemicals group Merck KGaA lifted its guidance range for full year earnings, citing strong sales of new drugs, biotech supplies and equipment as well as semiconductor materials during the third quarter.

Merck, Pfizer prevail in patent fight with Biogen over multiple sclerosis drug

Note: This story has been corrected to name Merck KGaA, not Merck & Co, in the first paragraph.

Merck KGaA says it has overcome production shortages in vaccine materials

* Life Science unit has invested more than 425 mln eur since 2017

Germany's Merck says it will focus on smaller takeovers

German drugs and chemicals maker Merck KGaA <MRCG.DE> said on Wednesday it would until 2022 focus on cutting its debt from the takeover of electronic materials company Versum and any acquisitions thereafter would likely be smaller ones.

Merck KGaA raises lower end of full-year profit guidance range

Merck KGaA <MRCG.DE> on Thursday was more upbeat about its worst-case scenario for full-year earnings, as patients previously deterred by lockdown measures begin to seek the company's treatments again.

Merck KGaA raises lower end of FY profit guidance range

Merck KGaA on Thursday was more upbeat about its worst-case scenario for full-year earnings, as patients previously deterred by lockdown measures begin to seek the company's treatments again.

BRIEF-Merck Announces Opening M Lab Collaboration Center In Shanghai

* MERCK KGAA, DARMSTADT, GERMANY ANNOUNCES OPENING OF ITS LIFE SCIENCE BUSINESS' LARGEST M LAB™ COLLABORATION CENTER IN SHANGHAI Source text for Eikon: Further company coverage: (Berlin Speed Desk)

Exclusive: EU secures potential COVID-19 drugs from Roche, Germany's Merck

The European Commission has struck deals with drugmakers Roche <ROG.S> and Merck KGaA <MRCG.DE> to secure supplies of experimental treatments for COVID-19, a Commission source told Reuters on Wednesday.

EXCLUSIVE-EU reaches deals with Roche, Merck for supply of COVID-19 drugs - source

The European Commission has reached agreements with pharmaceutical companies Roche and Merck KGaA to supply experimental drugs that can be used to treat COVID-19 patients, a commission source told Reuters on Wednesday.

EXCLUSIVE-EU reaches deals with Roche, Merck for supply of COVID-19 drugs - source

The European Commission has reached agreements with pharmaceutical companies Roche and Merck KGaA to supply experimental drugs that can be used to treat COVID-19 patients, a commission source told Reuters on Wednesday.

Sigma-Aldrich, not Merck gave misleading info in deal review, EU says

U.S. drugmaker Sigma-Aldrich provided incorrect and misleading information during an antitrust review of its 2015 takeover by Merck KGaA <MRCG.DE>, EU regulators said on Wednesday as they dropped the German company from their investigation.

BRIEF-Merck Receives Additional EU Statement In Proceedings Concerning Sigma-Aldrich Acquisition

* RECEIVES EU COMMISSION SUPPLEMENTARY STATEMENT OF OBJECTIONS IN THE PROCEEDINGS CONCERNING THE SIGMA-ALDRICH ACQUISITION

BRIEF-Merck KGaA: First Clinical Trial Of TLR7 And 8 Inhibitor As Treatment For Covid-19 Symptoms

* INITIATES FIRST CLINICAL TRIAL OF TLR7 AND 8 INHIBITOR AS A POTENTIAL TREATMENT FOR SEVERE SYMPTOMS OF COVID-19 INFECTION

BRIEF-Merck KGaA: EMA Validates Application For Cancer Drug Bavencio

* MERCK KGAA - EUROPEAN MEDICINES AGENCY VALIDATES APPLICATION FOR BAVENCIO® (AVELUMAB) FOR FIRST-LINE MAINTENANCE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

BRIEF-Shanghai Junshi Biosciences Signs Clinical Trial Collaboration & Supply Deal With Merck KGaA

* SIGNED CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK KGAA

BRIEF-Merck KGaA, Baylor College Announce Covid-19 Vaccine Collaboration

* MERCK AND BAYLOR COLLEGE OF MEDICINE COLLABORATE TO ADVANCE A VACCINE MANUFACTURING PLATFORM TO FIGHT COVID-19

BRIEF-Merck KGaA CEO Says We Will Have To Work Hard To Meet Our Targets

* WE WILL RAISE LIQUIDITY RESERVES TO ABOUT 3 BLN EURO TO BE PREPARED FOR ANYTHING - CFO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up